Moderna (NASDAQ:MRNA) Given New $96.00 Price Target at UBS Group

Moderna (NASDAQ:MRNA) had its price target cut by investment analysts at UBS Group from $108.00 to $96.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price would suggest a potential upside of 115.44% from the stock’s previous close.

A number of other research firms have also issued reports on MRNA. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Monday, November 18th. Jefferies Financial Group cut their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Leerink Partners dropped their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Barclays reduced their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Finally, The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.83.

Moderna Stock Down 6.2 %

NASDAQ:MRNA traded down $2.97 during trading hours on Wednesday, reaching $44.56. The company’s stock had a trading volume of 5,003,054 shares, compared to its average volume of 9,127,264. Moderna has a one year low of $35.80 and a one year high of $170.47. The business’s 50-day moving average is $43.38 and its 200-day moving average is $71.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market cap of $17.15 billion, a price-to-earnings ratio of -7.66 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.39) EPS. Equities research analysts predict that Moderna will post -9.3 EPS for the current year.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 2,664 shares of company stock worth $115,210 over the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. Private Advisor Group LLC grew its position in shares of Moderna by 112.1% during the 2nd quarter. Private Advisor Group LLC now owns 30,733 shares of the company’s stock worth $3,650,000 after purchasing an additional 16,243 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Moderna in the 2nd quarter valued at approximately $900,000. Caprock Group LLC boosted its position in Moderna by 66.2% in the second quarter. Caprock Group LLC now owns 5,122 shares of the company’s stock valued at $608,000 after buying an additional 2,040 shares in the last quarter. Quest Partners LLC raised its position in Moderna by 12,118.2% in the second quarter. Quest Partners LLC now owns 1,344 shares of the company’s stock valued at $160,000 after purchasing an additional 1,333 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in Moderna in the 2nd quarter valued at approximately $26,000. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.